title: 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
abstract: The purpose of this study was to evaluate the potential for therapy of thyroid tumors using the radiolabeled somatostatin (SS) analog octreotide.
  
  
  METHODS
  Concentrations of 111In activity in human thyroid tumors and normal thyroid tissue and blood samples were determined 1-15 d after intravenous injection of 111In-diethylenetriaminepentaacetic acid-Phe1-octreotide. The results were compared with SS receptor (sstr subtype profile (by Northern blot analysis) and the relative expression of the second subtype, sstr2 (by ribonuclease protection assay, RPA). The true tumor volumes in lymph node metastases from 1 patient were estimated. In total, tissues from 68 patients were included in the study.
  
  
  RESULTS
  The highest tumor-to-blood ratio (T/B) for medullary thyroid carcinoma (MTC) was 360; for follicular adenoma (FA), 190; for Hurthle cell adenoma (HCA), 140; and for Hurthle cell carcinoma (HCC) and papillary carcinoma (PC), 70. The corresponding value was 7-18 for normal thyroid tissue, with higher values for colloid goiter (8-48) and thyroiditis (7-120). A high T/B was related to a large fraction of tumor cells in lymph node metastases. T/Bs were higher for the tumor samples with expression of sstr2 at Northern blot analysis than for those without. All thyroid tumor types regularly expressed sstr1, sstr3, sstr4, and sstr5. sstr2 was expressed in most MTC tumors but was not detected in FA or PC and was irregularly expressed in HCA and HCC. However, RPA analysis detected sstr2 in all tumors studied.
  
  
  CONCLUSIONS
  Despite the lack of sstr2 at Northern blot analysis in most of the thyroid tumors studied, high T/Bs were in general found when compared with corresponding values for normal thyroid tissue. The sometimes extremely high ratios are promising and indicate a possibility of using radiolabeled octreotide for radiation therapy of sstr-positive tumors in the future.
authors.affiliation: Department of Radiation Physics, Sahlgrenska University Hospital, Göteborg University, Sweden.
authors.forename: E B
authors.initials: EB
authors.lastname: Forssell-Aronsson
authors.forename: O
authors.initials: O
authors.lastname: Nilsson
authors.forename: S A
authors.initials: SA
authors.lastname: Bejegård
authors.forename: L
authors.initials: L
authors.lastname: Kölby
authors.forename: P
authors.initials: P
authors.lastname: Bernhardt
authors.forename: J
authors.initials: J
authors.lastname: Mölne
authors.forename: S H
authors.initials: SH
authors.lastname: Hashemi
authors.forename: B
authors.initials: B
authors.lastname: Wängberg
authors.forename: L E
authors.initials: LE
authors.lastname: Tisell
authors.forename: H
authors.initials: H
authors.lastname: Ahlman
mesh_terms: D015152:Blotting, Northern; D006801:Humans; D007205:Indium Radioisotopes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D012333:RNA, Messenger / Q000235:genetics; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D017481:Receptors, Somatostatin / Q000145:classification / Q000378:metabolism*; D013961:Thyroid Gland / Q000378:metabolism; D013964:Thyroid Neoplasms / Q000378:metabolism / Q000532:radiotherapy*
chemical_list: D007205:Indium Radioisotopes; D012333:RNA, Messenger; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D004369:Pentetic Acid; D015282:Octreotide